🌍 It’s #WorldTBDay, and we need a new vaccine for the world’s deadliest infectious disease. Tuberculosis (TB) caused 1.25 million deaths in 2023 despite existing treatment options. A safe and effective vaccine would be a powerful tool to drive down #TB infections, morbidity, and deaths in high-burden countries and communities. Currently, there is only one licensed vaccine for TB: BCG, which was developed over 100 years ago and is only effective in children. It offers limited protection for adolescents and adults. The need for a new vaccine to augment the narrow protection offered by BCG is urgent. That’s why we were so excited to announce the kickoff of IAVI’s large-scale efficacy trial for MTBVAC, one of the most promising TB vaccine candidates in development today. ▶️ Learn more about MTBVAC and the IMAGINE clinical trial! Watch this video with commentary from IAVI staff. Further reading: https://www.vaccinestoday.eu/stories/are-new-tb-vaccines-finally-within-reach/ #EndTB #VaccinesWork (fb)

🔔 New IAVI Report Twenty-five years ago, the US declared #measles eliminated amid worldwide progress toward tackling the virus. In 2024, there were 16 separate US measles outbreaks, racking up 285 cases of the vaccine-preventable disease, according to the CDC. Only two months into 2025, there are nearly as many cases already and two deaths. What happened? In the first IAVI Report of 2025, Dr. Adam Ratner discusses his new book, "Booster Shots: The Urgent Lessons of Measles and the Uncertain Future of Children’s Health." He sheds light on the challenges facing the measles public health response as well as the immunology of this dangerous virus. Read the timely and sobering Q&A 👉 https://www.iavi.org/iavi-report/a-tragic-reminder-of-the-power-of-vaccination/ #VaccinesWork (fb)